Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

BACKGROUND: In several cardiovascular outcome trials (CVOTs), empagliflozin (SGLT-2 inhibitor), sitagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 receptor agonist) + standard of care (SoC) were compared to SoC in patients with type 2 diabetes and established cardiovascular disease (CVD). This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, Mafalda, Men, Peng, Wang, Xu, Ustyugova, Anastasia, Lamotte, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336098/
https://www.ncbi.nlm.nih.gov/pubmed/34348729
http://dx.doi.org/10.1186/s12962-021-00299-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336098/
https://www.ncbi.nlm.nih.gov/pubmed/34348729
http://dx.doi.org/10.1186/s12962-021-00299-z

Ejemplares similares